EA
TTPH

Emerald Acquisition’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Emerald Acquisition’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,702
Closed -$318K – 3080
2016
Q2 		$318K Buy
+3,702
New +$339K ﹤0.01% 2625

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Acquisition's TTPH Position: Q3 2016 in Review

Emerald Acquisition sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2016, closing a stake of 3,702 shares — an estimated $318K sold.

Emerald Acquisition first reported a position in TTPH in Q2 2016 and held it in 1 quarter. The position peaked at $318K in Q2 2016. 90 funds tracked by Wall St. Rank hold TTPH as of Q3 2016.

  • Emerald Acquisition reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 3,702 Tetraphase Pharmaceuticals, Inc. shares in Q3 2016, an estimated $318K.
  • Emerald Acquisition first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Tetraphase Pharmaceuticals, Inc. position peaked at $318K in Q2 2016.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.